Antisense Oligonucleotides Modulate SMN2 Splicing for SMA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal muscular atrophy (SMA) are limited, particularly for Type I, as they fail to effectively increase the inclusion of exon 7 in SMN2 transcripts, which is crucial for producing a functional survival motor neuron protein.
Innovation Solution
Development of antisense compounds targeting intron 6, exon 7, or intron 7 of the SMN2 gene with 2'-O-methoxyethyl sugar modifications, which modulate splicing to increase or decrease exon 7 inclusion, thereby potentially treating SMA by altering the splicing of SMN2 pre-mRNAs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for SMA, then current therapy protocols are maintained, but exon 7 inclusion in SMN2 transcripts is not effectively increased
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antisense oligonucleotides through 2'-O-methoxyethyl sugar modifications. This chemical parameter change enhances the compound's ability to bind to SMN2 pre-mRNA and modulate splicing, thereby increasing exon 7 inclusion efficiency and functional SMN protein production without compromising treatment reliability
Solution Approach 2:
The patent uses antisense compounds as intermediary molecules that mediate between the therapeutic goal and the molecular target. These compounds hybridize to specific sequences in SMN2 pre-mRNA (intron 6, exon 7, or intron 7) and act as intermediaries to redirect splicing patterns, enabling increased exon 7 inclusion and functional protein production while maintaining treatment reliability
2Productivity
If antisense compounds target SMN2 splicing to increase exon 7 inclusion, then functional SMN protein production is enhanced, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent applies local quality by introducing 2'-O-methoxyethyl modifications at specific positions within the oligonucleotide structure. Rather than uniformly modifying the entire molecule, the selective local modification enhances binding affinity and splicing modulation capability at critical regions while maintaining overall structural simplicity and manufacturability
Solution Approach 2:
The patent creates composite therapeutic compounds by combining natural nucleic acid backbone structures with synthetic 2'-O-methoxyethyl sugar modifications. This composite approach integrates the biological compatibility of natural oligonucleotides with the enhanced stability and affinity of modified structures, achieving high productivity while managing complexity through rational molecular design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense compounds effectively promote or inhibit exon 7 inclusion in SMN2 transcripts, providing a therapeutic approach to treat SMA by modulating splicing patterns, thereby increasing the production of functional SMN protein.
Implementation Method 1
antisense compounds targeted to and hybridizable with a nucleic acid molecule encoding SMN2
Data Source
AI summary
Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.